keyword
MENU ▼
Read by QxMD icon Read
search

Subcutaneous immunoglobulin

keyword
https://www.readbyqxmd.com/read/27900974/disseminated-mycobacteria-chelonae-infection-in-a-kidney-pancreas-transplant-recipient-a-case-report-and-review-of-the-literature
#1
Shafi Malik, Ananda Ghosh, Shahid Husain
A 40-year-old male with a long-standing history of type 1 diabetes with end-stage renal failure underwent combined kidney-pancreas (KP) transplant from a standard criteria donor. Post-operative course was uncomplicated with good primary function of both transplant grafts. Induction was with thymoglobulin and maintenance immunosuppression was with tacrolimus, mycophenolate mofetil and prednisolone. Nine weeks post-transplant, the patient developed dysfunction of both grafts. Panel reactive antibody testing revealed that the patient had developed a de novo donor-specific antibody and considering an antibody-mediated rejection the patient was treated with intravenous pulse methyl prednisone 500 mg ×3 doses, IV immunoglobulin 2 mg/kg in two divided doses, and ATG 7 mg/kg (total dose of 700 mg)...
November 2016: Saudi Journal of Kidney Diseases and Transplantation
https://www.readbyqxmd.com/read/27893674/relapsing-remitting-lesions-in-a-woman-with-progressive-hemifacial-atrophy-and-chronic-hepatitis-b-virus-infection-a-case-report
#2
Ying Zhang, Mingqin Zhu, Xiaozhen Li, Jing Miao, Chenchen Duan, Li Cui, Xuefan Yu
INTRODUCTION: Progressive hemifacial atrophy (PHA) is a rare disorder characterized by unilateral facial atrophy affecting the skin, subcutaneous tissue, and fat, muscle, and osteocartilagenous structures creating a sunken hemiface appearance.Etiopathogenesis of PHA is poorly understood; no definitive treatment is currently available. CLINICAL FINDINGS: We report a 41-year-old woman with PHA who showed an uncharacteristic "relapsing-remitting" evolution of brain lesions and was seropositive for hepatitis B virus (HBV)...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27884454/-management-of-adverse-effects-related-to-human-immunoglobulin-therapy-recommendations-for-clinical-practice
#3
I Marie, P Chérin, M Michallet, E Pelus, J Dantal, J-C Crave, J-C Delain, J-F Viallard
Both intravenous and subcutaneous immunoglobulins are therapeutic modalities approved in various conditions, including primary and secondary immune deficiencies and autoimmune disorders. To date, immunoglobulins have more often been considered as a safe medication, with minor adverse effects such as hypertension, fever and chills, nausea, myalgia or headache. However, with the wider use of immunoglobulins in the treatment of autoimmune diseases, severe side effects have also been reported to occur in immunoglobulin-treated patients, especially anaphylaxis, aseptic meningitis, acute renal impairment, thrombotic events as well as haematological manifestations...
November 21, 2016: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/27876304/effective-use-of-20-subcutaneous-immunoglobulin-therapy-in-a-man-with-preexisting-thrombi
#4
Carla Duff, Mandel R Sher, Jennifer W Leiding
No abstract text is available yet for this article.
November 18, 2016: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/27861229/what-s-in-the-literature
#5
Nicholas J Silvestri, Gil I Wolfe, David Lacomis
In this edition, we focus on neuromuscular junction disorders and myopathy. The newly published international consensus guidelines for the management of myasthenia gravis are reviewed. In addition, various emerging treatment options for myasthenia, including the use of methotrexate, rituximab, subcutaneous immunoglobulin, and thymectomy, are discussed. Recent studies examining the clinical and genetic features of several forms of congenital myasthenia gravis are also highlighted. The clinical features and treatment of late-onset Pompe disease are reviewed, as are studies in facioscapulohumeral dystrophy, idiopathic inflammatory myopathies, and calpainopathy...
December 2016: Journal of Clinical Neuromuscular Disease
https://www.readbyqxmd.com/read/27860553/developing-an-inactivated-rotavirus-vaccine-and-evaluating-the-immunogenicity-against-a-commercially-available-attenuated-rotavirus-vaccine-using-a-mice-animal-model
#6
Ayaa S M Hashim, Khaled M A Aboshanab, Aly F M El-Sayed
There is a high demand for public immunization against Rotavirus (RV), especially in Africa. In Africa, the attenuated RV vaccination is contraindicated in patients with immune diseases and nutrition deficiency. Therefore, the inactivated RV vaccine (IRVV) could be an alternative. In this study, we aimed to develop a pentavalent-IRVV using the most circulating RV strains in Egypt and evaluate it against the commercially available Rotarix(®) vaccine. Trial-IRVV was developed with 5% sucrose, 2% polysorbate-80, and adsorbed on Alum to potentiate the vaccine immune response...
November 18, 2016: Viral Immunology
https://www.readbyqxmd.com/read/27849353/evaluating-dose-ratio-of-subcutaneous-to-intravenous-immunoglobulin-therapy-among-patients-with-primary-immunodeficiency-disease-switching-to-20-subcutaneous-immunoglobulin-therapy
#7
Girishanthy Krishnarajah, Jee-Yeon K Lehmann, Brian Ellman, Rachel H Bhak, Maral DerSarkissian, Deane Leader, Ann L Bullinger, Mei Sheng Duh
BACKGROUND: Current prescribing information recommends that physicians apply a dose ratio of 1.37:1 (1.53:1 prior to January 2015) in the United States (US) when switching patients with primary immunodeficiency disease (PI) from intravenous (IVIG) therapy to most subcutaneous therapy ([SCIG], except the 10% SCIG human hyaluronidase and immune globulin). However, a dose ratio of 1:1 was studied and approved for the European Union (EU). The dose-adjustment ratio used by prescribers in real-world US clinical practice is unknown...
October 2016: American Journal of Managed Care
https://www.readbyqxmd.com/read/27836057/the-nuts-and-bolts-of-immunoglobulin-treatment-for-antibody-deficiency
#8
Richard L Wasserman
Immunoglobulin therapy is a key element in the management of most patients with primary immunodeficiency disease. Allergist/immunologists should be familiar with the appropriate evaluation of candidates for immunoglobulin, the characteristics of immunoglobulin products, and how to use them to provide the best care to their patients. Available immunoglobulin products appear to be equally efficacious, but they are not interchangeable. Minimizing the risk of serious adverse events and controlling minor side effects is important to ideal patient care...
November 2016: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/27828933/practical-considerations-for-self-administration-of-subcutaneous-immunoglobulin-g-utilizing-recombinant-human-hyaluronidase-an-advanced-method-of-subcutaneous-administration-a-nurse-s-perspective
#9
Linda K Miars, Michelle Tran, Kimberly Duff
An approved subcutaneous infusion of immunoglobulin G using recombinant human hyaluronidase (IGHy) allows adult patients with primary immunodeficiency disease to self-administer every 3 to 4 weeks using 1 to 2 subcutaneous infusion site(s). This article reviews the practical considerations for nurses to simplify patient education and training. Key considerations include pump choice and parameters, ancillary supplies, and technique. Patient education includes infusion log upkeep and management of potential reactions...
November 2016: Journal of Infusion Nursing: the Official Publication of the Infusion Nurses Society
https://www.readbyqxmd.com/read/27822850/population-pharmacokinetics-pk-and-pharmacodynamics-pd-analysis-of-ly3015014-a-monoclonal-antibody-to-protein-convertase-subtilisin-kexin-type-9-pcsk9-in-healthy-subjects-and-hypercholesterolemia-patients
#10
Tong Shen, Douglas E James, Kathryn A Krueger
PURPOSE: LY3015014 is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that binds to the catalytic domain of PCSK9 and reduce low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia that is poorly controlled by maximally tolerated statin therapy. The objective of this pharmacokinetic/pharmacodynamics (PK/PD) analysis was to characterize the PK and PD properties of LY3015014 and assess the effect of covariates on the LY3015014 PK-PD profiles. METHODS: Single and multiple dose data from three phase1 studies in healthy subjects (n = 133), as well as a phase 2 study in hypercholesterolemia patients (n = 527) were combined into a single dataset for analysis...
November 7, 2016: Pharmaceutical Research
https://www.readbyqxmd.com/read/27807853/aseptic-meningitis-following-therapy-with-immune-globulins-a-combination-of-product-features-and-patient-characteristics
#11
Roger Berg, Elisabeth Fuellenhals
BACKGROUND: Aseptic meningitis (AM) represents a recognized side effect of immune globulin (IG) therapy and may warrant additional diagnostic procedures and therapy with anti-infective drugs until a definite diagnosis can be established. Although, to date, only small case series have been published, the objective of the current study was to investigate a large case series of patients with AM. STUDY DESIGN AND METHODS: The pharmacovigilance safety database of a 10% liquid IG (Gammagard Liquid) was queried for all reports of AM...
November 2, 2016: Transfusion
https://www.readbyqxmd.com/read/27763809/do-australian-immunoglobulin-products-meet-international-measles-antibody-titre-standards
#12
Megan K Young, Joseph Bertolini, Pushpa Kotharu, Darryl Maher, Allan W Cripps
The effectiveness of passive immunisation post-exposure to measles appears subject to a dose-response effect. New Zealand and the United Kingdom have increased the recommended dose of polyclonal human immunoglobulin for post-exposure prophylaxis within the last decade in response to concerns about decreasing levels of measles antibodies in these products. This study used the plaque-reduction neutralization test (PRNT) to measure the titre of measles-specific antibodies in Australian immunoglobulin products for post-exposure prophylaxis and compared the utility of an enzyme-linked immunosorbent assay (ELISA) to the PRNT in available Australian and international samples: Australian intramuscular (n = 10), Australian intravenous (n = 28), New Zealand intramuscular (n = 2), Hizentra (subcutaneous)(USA) (n = 3), and Privigen (intravenous)(USA) (n = 2)...
October 20, 2016: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/27745563/impact-of-feed-restriction-and-housing-hygiene-conditions-on-specific-and-inflammatory-immune-response-the-cecal-bacterial-community-and-the-survival-of-young-rabbits
#13
S Combes, K Massip, O Martin, H Furbeyre, L Cauquil, G Pascal, O Bouchez, N Le Floc'h, O Zemb, I P Oswald, T Gidenne
Limiting the post-weaning intake of the young rabbit is known to improve its resistance to digestive disorders, whereas a degradation of its housing hygiene is assumed to have a negative impact on its health. This study aims at providing insights into the mechanism of digestive health preservation regarding both host (growth and immune response) and its symbiotic digestive microbiota. A 2×2 factorial design from weaning (day 28) to day 64 was set up: ad libitum intake or restricted intake at 70% of ad libitum, and high v...
October 17, 2016: Animal: An International Journal of Animal Bioscience
https://www.readbyqxmd.com/read/27684521/protective-efficacy-and-pulmonary-immune-response-following-subcutaneous-and-intranasal-bcg-administration-in-mice
#14
Santiago Uranga, Dessislava Marinova, Carlos Martin, Nacho Aguilo
Despite global coverage of intradermal BCG vaccination, tuberculosis remains one of the most prevalent infectious diseases in the world. Preclinical data have encouraged pulmonary tuberculosis vaccines as a promising strategy to prevent pulmonary disease, which is responsible for transmission. In this work, we describe the methodology used to demonstrate in the mouse model the benefits of intranasal BCG vaccination when compared to subcutaneous. Our data revealed greater protective efficacy following intranasal BCG administration...
2016: Journal of Visualized Experiments: JoVE
https://www.readbyqxmd.com/read/27649063/subcutaneous-vs-intravenous-immunoglobulin-for-chronic-autoimmune-neuropathies-a-meta-analysis
#15
Juan M Racosta, Luciano A Sposato, Kurt Kimpinski
INTRODUCTION: High-dose intravenous immunoglobulin (IVIg) is an evidence-based treatment for multifocal motor neuropathy (MMN) and chronic inflammatory demyelinating polyneuropathy (CIDP). Recently, subcutaneous immunoglobulin (SC-Ig) has received increasing attention. METHODS: We performed a meta-analysis of reports of efficacy and safety of SC-Ig versus IVIg for inflammatory demyelinating polyneuropathies. RESULTS: A total of 8 studies comprising 138 patients (50 with MMN and 88 with chronic CIDP) were included in the meta-analysis...
September 20, 2016: Muscle & Nerve
https://www.readbyqxmd.com/read/27638480/clinical-use-and-therapeutic-potential-of-ivig-scig-plasma-derived-iga-or-igm-and-other-alternative-immunoglobulin-preparations
#16
Peter J Späth, Christoph Schneider, Stephan von Gunten
Intravenous and subcutaneous immunoglobulin preparations, consisting of IgG class antibodies, are increasingly used to treat a broad range of pathological conditions, including humoral immune deficiencies, as well as acute and chronic inflammatory or autoimmune disorders. A plethora of Fab- or Fc-mediated immune regulatory mechanisms has been described that might act separately or in concert, depending on pathogenesis or stage of clinical condition. Attempts have been undertaken to improve the efficacy of polyclonal IgG preparations, including the identification of relevant subfractions, mild chemical modification of molecules, or modification of carbohydrate side chains...
September 16, 2016: Archivum Immunologiae et Therapiae Experimentalis
https://www.readbyqxmd.com/read/27637321/utility-of-solution-x-ray-scattering-for-the-development-of-antibody-biopharmaceuticals
#17
Hideyo Inouye, Damian Houde, Deniz B Temel, Lee Makowski
Characterization of immunoglobulin solutions at high concentrations represents a significant challenge. A current trend in the biopharmaceutical industry is to manufacture highly concentrated drug products, which can be used to deliver high doses in small volumes, via subcutaneous injections. Studying a molecule's structure and properties in its final drug product formulation is ideal, but characterization is typically performed under dilute solution conditions with critical stabilizing buffer components removed because of interference effects, which can result in an incomplete understanding of the molecule's properties...
November 2016: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/27636578/bisphosphonates-inhibit-pain-bone-loss-and-inflammation-in-a-rat-tibia-fracture-model-of-complex-regional-pain-syndrome
#18
Liping Wang, Tian-Zhi Guo, Tzuping Wei, Wen-Wu Li, Xiaoyou Shi, J David Clark, Wade S Kingery
BACKGROUND: Bisphosphonates are used to prevent the bone loss and fractures associated with osteoporosis, bone metastases, multiple myeloma, and osteogenesis deformans. Distal limb fractures cause regional bone loss with cutaneous inflammation and pain in the injured limb that can develop into complex regional pain syndrome (CRPS). Clinical trials have reported that antiresorptive bisphosphonates can prevent fracture-induced bone loss, inhibit serum inflammatory cytokine levels, and alleviate CRPS pain...
October 2016: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/27613250/efficacy-safety-tolerability-and-pharmacokinetics-of-a-novel-human-immune-globulin-subcutaneous-20-a-phase-2-3-study-in-europe-in-patients-with-primary-immunodeficiencies
#19
M Borte, G Kriván, B Derfalvi, L Maródi, T Harrer, S Jolles, C Bourgeois, W Engl, H Leibl, B McCoy, D Gelmont, L Yel
A highly concentrated (20%) immunoglobulin (Ig)G preparation for subcutaneous administration (IGSC 20%), would offer a new option for antibody replacement therapy in patients with primary immunodeficiency diseases (PIDD). The efficacy, safety, tolerability and pharmacokinetics of IGSC 20% were evaluated in a prospective trial in Europe in 49 patients with PIDD aged 2-67 years. Over a median of 358 days, patients received 2349 IGSC 20% infusions at monthly doses equivalent to those administered for previous intravenous or subcutaneous IgG treatment...
September 10, 2016: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/27602116/cetuximab-intensifies-the-adcc-activity-of-adoptive-nk-cells-in-a-nude-mouse-colorectal-cancer-xenograft-model
#20
Shanshan Chen, Xuechun Li, Rongming Chen, Mingang Yin, Qiuhong Zheng
Natural killer (NK) cells, discovered ~40 years ago, are believed to be the most effective cytotoxic lymphocytes to counteract cancer; however, adoptive NK cell therapy in vivo has encountered certain limitations, including a lack of specificity. The drug cetuximab can mediate antibody dependent cell mediated cytotoxicity (ADCC) activity through NK cells in vivo, and has been approved for the first-line treatment of epidermal growth factor receptor (EGFR)-positive metastatic colorectal cancer (CRC). However, the ADCC activity of adoptive NK cells, induced by cetuximab in a nude mouse CRC xenograft model, has not been previously reported...
September 2016: Oncology Letters
keyword
keyword
54047
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"